D-0472-2025 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0472-2025 was initiated by Eugia US LLC on May 29, 2025 and is designated Class II. Reason for recall: Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis. The recall status is ongoing. Affected quantity: 48,000 vials.

Recall details

Product Type
Drugs
Report Date
Jun 25, 2025
Initiation Date
May 29, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
48,000 vials

Product description

Gentamicin Injection, USP, (PEDIATRIC), 20 mg per 2 mL (10 mg per mL*), 2 mL Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ, 08520 Vial- NDC 55150-401-01, Carton NDC 55150-401-25

Reason for recall

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Distribution pattern

Nationwide in the USA

Code information

Batch 3GT23006, 3GT23007, 3GT23008, Exp Date: November, 30, 2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0472-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0472-2025. Report a data issue: hello@regdatalab.com.